141 related articles for article (PubMed ID: 387592)
21. Synergistic activity of components of mycobacteria and mutant Salmonella in causing regression of line-10 tumors in guinea pigs.
McLaughlin CA; Hargrave SL; Bickel WD; Ribi E
Cancer Res; 1979 May; 39(5):1766-71. PubMed ID: 371795
[No Abstract] [Full Text] [Related]
22. Responses of tumors induced in inbred guinea pig strain JY=1 and strain Hartley/F to BCG.
Kataoka T; Tokunaga T; Murohashi T
J Natl Cancer Inst; 1977 Mar; 58(3):803-8. PubMed ID: 320348
[TBL] [Abstract][Full Text] [Related]
23. Properties of TAS-1D3, a tuberculin-active substance from BCG, in regard to delayed hypersensitivity.
Yano O; Toizumi S; Sudo T
Microbiol Immunol; 1984; 28(10):1149-57. PubMed ID: 6441106
[TBL] [Abstract][Full Text] [Related]
24. Induced sensitization to nickel in guinea pigs immunized with mycobacteria by injection of purified protein derivative with nickel.
Kitaura H; Nakao N; Yoshida N; Yamada T
New Microbiol; 2003 Jan; 26(1):101-8. PubMed ID: 12578317
[TBL] [Abstract][Full Text] [Related]
25. Immunoprotection against murine bladder carcinoma by octaarginine-modified liposomes incorporating cell wall of Mycobacterium bovis bacillus Calmette-Guérin.
Joraku A; Homhuan A; Kawai K; Yamamoto T; Miyazaki J; Kogure K; Yano I; Harashima H; Akaza H
BJU Int; 2009 Mar; 103(5):686-93. PubMed ID: 19040525
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy of metastatic cancer in guinea pigs: failure of intralesional BCG to influence the results of radical surgery.
Hunter JT; Okuda T; Rapp HJ
J Natl Cancer Inst; 1977 Nov; 59(5):1435-9. PubMed ID: 909107
[TBL] [Abstract][Full Text] [Related]
27. Suppression of BCG cell wall-induced delayed-type hypersensitivity by BCG pre-treatment. II. Induction of suppressor T cells by heat-killed BCG injection.
Kato K; Yamamoto K
Immunology; 1982 Apr; 45(4):655-61. PubMed ID: 6175566
[TBL] [Abstract][Full Text] [Related]
28. Histologic and ultrastructural studies of tumor regression in inbred guinea pigs after intralesional injection of Mycobacterium bovis (BCG).
Hanna MG; Snodgrass MJ; Zbar B; Rapp HJ
Natl Cancer Inst Monogr; 1973 Dec; 39():71-85. PubMed ID: 4362524
[No Abstract] [Full Text] [Related]
29. Suppression and immunotherapy of the guinea pig line 10 hepatocarcinoma mediated by heat-killed disrupted Mycobacterium bovis strain Bacillus Calmette-Guérin.
Minden P; Mathews HL
Cancer Res; 1980 Sep; 40(9):3214-7. PubMed ID: 6159072
[TBL] [Abstract][Full Text] [Related]
30. In vivo and in vitro boosting effects of tuberculin skin tests in guinea-pigs immunized with living BCG or with killed Mycobacterium tuberculosis.
Hasløv K; Møller S; Bentzon MW
Acta Pathol Microbiol Immunol Scand C; 1984 Apr; 92(2):101-6. PubMed ID: 6375252
[TBL] [Abstract][Full Text] [Related]
31. Response to Mycobacterium bovis BCG vaccination in protein- and zinc-deficient guinea pigs.
McMurray DN; Yetley EA
Infect Immun; 1983 Feb; 39(2):755-61. PubMed ID: 6339390
[TBL] [Abstract][Full Text] [Related]
32. The efficacy of live tuberculosis vaccines after presensitization with Mycobacterium avium.
de Lisle GW; Wards BJ; Buddle BM; Collins DM
Tuberculosis (Edinb); 2005; 85(1-2):73-9. PubMed ID: 15687030
[TBL] [Abstract][Full Text] [Related]
33. Immunotherapy of human malignant melanoma with oil-attached BCG cell-wall skeleton.
Yamamura Y; Yoshizaki K; Azuma I; Yagura T; Watanabe T
Gan; 1975 Aug; 66(4):355-63. PubMed ID: 1102379
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of BCG administered by scarification for immunotherapy of metastatic hepatocarcinoma in the guinea pig.
Hanna MG; Peters LC; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1976 May; 56(5):1013-7. PubMed ID: 186611
[TBL] [Abstract][Full Text] [Related]
35. Effects of sequential intravesical administration of mitomycin C and bacillus Calmette-Guérin on the immune response in the guinea pig bladder.
Balemans LT; Vegt PD; Steerenberg PA; De Boer EC; Van Swaaij A; De Vries RE; Van der Meijden AP; Den Otter W
Urol Res; 1994; 22(4):239-45. PubMed ID: 7871637
[TBL] [Abstract][Full Text] [Related]
36. Comparative studies with various substrains of Mycobacterium bovis BCG on the production of an antigenic protein, MPB70.
Miura K; Nagai S; Kinomoto M; Haga S; Tokunaga T
Infect Immun; 1983 Feb; 39(2):540-5. PubMed ID: 6339381
[TBL] [Abstract][Full Text] [Related]
37. Identification of a Mycobacterium bovis BCG 45/47-kilodalton antigen complex, an immunodominant target for antibody response after immunization with living bacteria.
Romain F; Laqueyrerie A; Militzer P; Pescher P; Chavarot P; Lagranderie M; Auregan G; Gheorghiu M; Marchal G
Infect Immun; 1993 Feb; 61(2):742-50. PubMed ID: 8423100
[TBL] [Abstract][Full Text] [Related]
38. Immunotherapy of cancer: tumor suppression and regression by cell walls of Mycobacterium phlei attached to oil droplets.
Gray GR; Ribi E; Granger D; Parker R; Azuma I; Yamamoto K
J Natl Cancer Inst; 1975 Sep; 55(3):727-30. PubMed ID: 1159851
[TBL] [Abstract][Full Text] [Related]
39. A specific vaccine effective against stage I and stage II malignant disease in guinea pigs. Effect of variations in preparations and storage.
Yarkoni E; Hunter JT; Sukumar S
Cancer Immunol Immunother; 1982; 14(2):92-5. PubMed ID: 6965232
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy of bilateral lymph node metastases in guinea pigs by intralesional or paralesional injection of Mycobacterium bovis (BCG).
Zbar B; Hunter JT; Rapp HJ; Canti GF
J Natl Cancer Inst; 1978 May; 60(5):1163-8. PubMed ID: 642033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
